Abstract 3705
Background
The impact of pregnancy on clinico-pathological features and prognosis of breast cancer remains controversial.We aimed to evaluate the impact of the association of pregnancy with breast cancer on tumor feature and prognosis- overall survival (OS) and disease free survival (DFS).
Methods
We defined Pregnancy Associated Breast Cancer (PABC) as breast cancer diagnosed during pregnancy or within a year following delivery. We enrolled PABC patients(pts) treated at our institution between December 2012 and December 2017 , and for each case, one non-PABC control was matched for stage, age, and year of diagnosis. Chis-quare and Fisher’s exact test, the Kaplan-Meier method, and Cox’s regression model were used. Univariate and multivariate analyses were performed to assess the parameters associated with prognosis.
Results
41 women with PABC were identified; 22 pts were diagnosed during pregnancy and 19 were diagnosed within one year of postpartum. There were more PR negative and triple negative tumors in the PABC(56.1% and 24.4%) than in the non-PABC(31.7% and 4.9%) (p = 0.045 and 0.026 respectively). The HER2 positivity was the same in the two group, both 31.7%. Median DFS in PABC pts was 29.0 months (95% CI range 6.5-51.5 months ) compared with 40.9 months (95% CI range 22.8–58.8 months) in the non-PABC pts(p = 0.167). Median OS in two groups were similar and even longer in PABC group, 82.8 months in PABC pts range(95% CI 39.3-126.5months) compared with 80.1 months (95% CI range 56.7-103.6months) in the non-PABC pts( p = 0.131).
Conclusions
The results show histological features were similar in both groups, except that triple-negative tumors were more common in the PABC group. The survival analyses show similar OS for patients diagnosed with PABC compared with non-PABC patients, and DFS tends to be shorter for PABC but no significant difference was observed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5489 - Local immune status in cancer cell nests can be a predictor of survival for rectal cancer with neoadjuvant radiotherapy
Presenter: xijin lin
Session: Poster Display session 2
Resources:
Abstract
1653 - Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study.
Presenter: Clémence Brun
Session: Poster Display session 2
Resources:
Abstract
5206 - Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer.
Presenter: Per Pfeiffer
Session: Poster Display session 2
Resources:
Abstract
2992 - Clinical impact of mucinous and poorly differentiated tumors on the outcome of patients with stage II colon cancer: a TOSCA subgroup analysis
Presenter: Gerardo Rosati
Session: Poster Display session 2
Resources:
Abstract
4753 - Exercise improved adjuvant treatment completion rates and treatment-related toxicities in colorectal cancer: A prospective pilot study
Presenter: Hong Jun Kim
Session: Poster Display session 2
Resources:
Abstract
2735 - Bevacizumab plus Oxaliplatin-Based Chemotherapy as Adjuvant Treatment for Colon Cancer (CC): Updated analysis of stage II disease from the AVANT Phase III Randomized trial by the GERCOR Group
Presenter: Aimery De Gramont
Session: Poster Display session 2
Resources:
Abstract
1843 - Multicenter Validation of the Postoperative Carcinoembryonic Antigen Combined Prognostic Model for Stage Ⅲ Colon Cancer
Presenter: Ji Zhu
Session: Poster Display session 2
Resources:
Abstract
2554 - Impact of the IDEA study on clinical practice for stage III colon cancer patients: a French GERCOR - FFCD - GI UNICANCER national survey.
Presenter: Kaissa Ouali
Session: Poster Display session 2
Resources:
Abstract
3285 - Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Presenter: Philip Falk
Session: Poster Display session 2
Resources:
Abstract
3905 - Loss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer
Presenter: Krittiya Korphaisarn
Session: Poster Display session 2
Resources:
Abstract